Bionaturis (Public MAB) is a public-owned biopharmaceutical company, listing in the Spanish MAB stock exchange, developing and producing biological products for the pharmaceutical and veterinarian sectors. Bionaturis specializes in the prevention and treatment of niche diseases, such as orphan diseases.
Bionaturis preserves its core vision of a global access to health, estimulating the progress by constant innovation such as to make complex biologicals drugs more feasible to people and producers all around the world by means of the FLYLIFE concept.
As value proposition Bionaturis has chosen Nature as an optimized source for the production of biopharmaceuticals, substituting the traditional industrial cumbersome steel reactors for single use, disposable and naturally occurring individual reactors: FLYLIFE. FLYLIFE makes use of natural resources to achieve and indeed surpass the productive capacity of traditional industry standards but utilizing up to ten-fold less space and fifteen-fold less investment. Amongst others, in niche markets where currently there is no solution, these competitive advantages provide a profitable solution and gives renewed hope to millions of worldwide patients.
Their mission is to take leader positions within the field of new platforms for production of biopharmaceuticals for veterinary and human use.